Formoterol and mometasone combination inhalers are for oral inhalation only. The specific instructions vary by brand and device type (e.g., metered-dose inhaler [MDI], dry powder inhaler [DPI]). Always read the patient instructions provided with your specific inhaler device carefully.
- General Inhalation Instructions:
- Proper Technique is Key: Ensure you are taught and regularly review the correct inhalation technique by a healthcare professional. Incorrect technique can significantly reduce medication delivery to the lungs.
- Priming: If it’s an MDI (like Dulera), shake the canister well before each use. The inhaler may need to be primed (e.g., by releasing test sprays into the air) before the first use or if it hasn’t been used for several days.
- Exhale: Breathe out fully, away from the mouthpiece, emptying your lungs as much as possible.
- Inhale: Place your lips tightly around the mouthpiece and inhale deeply and steadily (for MDIs) or quickly and deeply (for DPIs), as instructed.
- Hold Breath: Remove the inhaler from your mouth and hold your breath for about 5-10 seconds (or as long as comfortable) to allow the medication to settle in the lungs.
- Exhale Slowly: Exhale slowly.
- Repeat (if applicable): If your dose requires two puffs, wait the recommended time (e.g., 30 seconds to 1 minute) before taking the second puff, following the same steps.
- Rinse Mouth: Always rinse your mouth thoroughly with water and spit it out after the final dose. Do not swallow the water. This step is crucial to prevent common side effects like oral thrush (fungal infection in the mouth) and hoarseness associated with inhaled corticosteroids.
- Dosing Schedule:
- For asthma, the typical dose is two inhalations (puffs) twice daily, usually in the morning and in the evening. The doses should be approximately 12 hours apart.
- The strength (e.g., mcg of mometasone/mcg of formoterol per puff) will be prescribed by your doctor based on your asthma severity and previous treatment.
- Do not take more than two inhalations twice daily or exceed the prescribed total daily dose.
- Important Reminders:
- Not a Rescue Inhaler: This medication will not provide immediate relief for sudden breathing problems. Always carry your prescribed short-acting rescue inhaler.
- Consistent Use: Use this medication regularly, every day, even if you feel well, to maintain its benefits and prevent asthma attacks. Do not stop using it suddenly without consulting your doctor.
- Administration: Oral inhalation (MDI).
- Frequency: Two puffs twice daily (morning and evening).
- Essential Step: Rinse mouth and spit water after each use.
- Critical: Not for acute relief; use consistently as prescribed.
The combination of formoterol and mometasone provides a comprehensive approach to asthma management by addressing both airway constriction and inflammation:
- Formoterol (LABA):
- Acts on beta2-adrenergic receptors found in the smooth muscles of the airways.
- Stimulation of these receptors leads to increased cyclic adenosine monophosphate (cAMP) inside the cells.
- This causes the bronchial smooth muscles to relax, leading to bronchodilation (widening of the airways).
- Formoterol has a rapid onset of action (within minutes) and provides effects lasting up to 12 hours, allowing for twice-daily dosing.
- Mometasone (ICS):
- Is a potent anti-inflammatory corticosteroid.
- It works by reducing the inflammation (swelling and irritation) in the airways that is a hallmark of asthma.
- Mometasone inhibits various inflammatory cells (e.g., mast cells, eosinophils, lymphocytes) and mediators (e.g., histamine, cytokines, leukotrienes) involved in the asthmatic response.
- Reducing inflammation helps to decrease airway hyperresponsiveness, reduce mucus production, and prevent asthma symptoms and exacerbations over time.
By combining these two agents, the medication effectively opens the airways and simultaneously reduces the underlying inflammation, leading to better long-term control of asthma symptoms, improved lung function, and a reduction in the frequency and severity of asthma attacks.
- Dual Mechanism: Formoterol (LABA) provides rapid and long-lasting bronchodilation; Mometasone (ICS) reduces airway inflammation.
- Synergistic Effect: Addresses both bronchoconstriction and inflammation for comprehensive asthma control.
- Outcome: Improved lung function, reduced symptoms, fewer exacerbations.
Like all medications, formoterol and mometasone can cause side effects. Patients should be aware of these and report any concerning or persistent symptoms to their healthcare provider.
- Common Side Effects:
- Headache
- Nasal congestion, sinusitis, or pharyngitis (sore throat)
- Oral candidiasis (thrush) – white patches in the mouth or throat. This is a fungal infection common with inhaled corticosteroids and can often be prevented by rinsing the mouth after use.
- Dysphonia (hoarseness)
- Cough
- Nausea, vomiting
- Tremor, nervousness, dizziness (related to formoterol)
- Muscle cramps
- Insomnia (difficulty sleeping)
- Serious Side Effects (Seek immediate medical attention if these occur):
- Paradoxical Bronchospasm: Sudden worsening of breathing, wheezing, or coughing immediately after using the inhaler. Stop use and use your rescue inhaler.
- Serious Asthma-Related Events: While the combination reduces the risk compared to LABA monotherapy, there is still a “Black Box Warning” associated with LABAs.
- Cardiovascular Effects: Fast or irregular heartbeat (tachycardia, palpitations, arrhythmias), chest pain, increased blood pressure.
- Immunosuppression: Mometasone, being a corticosteroid, can weaken the immune system, increasing the risk of infections (e.g., chickenpox, measles, tuberculosis).
- Adrenal Suppression: Long-term use of high doses can lead to adrenal insufficiency, where the body does not produce enough natural corticosteroids.
- Bone Mineral Density (BMD) Reduction: Long-term use of inhaled corticosteroids can lead to decreased bone density and increased risk of osteoporosis, especially in at-risk individuals.
- Eye Problems: Increased intraocular pressure, glaucoma, and cataracts have been reported with long-term inhaled corticosteroid use.
- Growth Suppression: In children, long-term use of inhaled corticosteroids can lead to a slight reduction in growth velocity.
- Hyperglycemia: Increased blood sugar levels, particularly in diabetic patients.
- Allergic Reactions: Rash, hives, swelling of the face, lips, tongue, or throat, difficulty breathing.
- Common: Headache, sore throat, oral thrush, hoarseness, tremor.
- Serious (require immediate attention): Paradoxical bronchospasm, cardiovascular issues, immunosuppression, adrenal suppression, bone loss, eye problems, growth suppression (in children), hyperglycemia.
Prevention: Rinse mouth after use to prevent oral thrush.
Due to the nature of its active components, formoterol and mometasone carry several critical warnings and precautions.
- Asthma-Related Death (Black Box Warning): For asthma, this combination medication is indicated only for patients not adequately controlled on an inhaled corticosteroid alone or whose disease warrants both an ICS and a LABA. It is NOT for asthma patients adequately controlled on low or medium-dose inhaled corticosteroids alone. The LABA component (formoterol) has been associated with an increased risk of asthma-related death when used as monotherapy.
- Not for Acute Symptoms: This medication is for long-term maintenance and will not provide rapid relief for acute bronchospasm or asthma attacks. Always use a short-acting rescue inhaler for sudden symptoms.
- Not a Substitute for Oral Corticosteroids: Do not use this medication to relieve acute symptoms that would typically require oral corticosteroids. Patients on oral corticosteroids should not stop or reduce their dose without medical supervision.
- Worsening Asthma: Do not initiate this medication during an acute or rapidly worsening asthma episode. If asthma worsens or the patient needs their rescue inhaler more often, seek immediate medical attention. Do not increase the prescribed dose.
- Immunosuppression and Infections: Mometasone can weaken the immune system, making patients more susceptible to infections (e.g., chickenpox, measles, tuberculosis, fungal infections). Avoid exposure to sick individuals if possible, and report any signs of infection.
- Adrenal Suppression: Long-term use of high doses can lead to adrenal suppression. Patients transitioning from oral corticosteroids to inhaled corticosteroids, or those experiencing stress (e.g., surgery, trauma, severe infection), may require supplemental systemic corticosteroids.
- Cardiovascular Effects: Use with caution in patients with cardiovascular disorders (e.g., coronary insufficiency, cardiac arrhythmias, hypertension), as formoterol can increase heart rate and blood pressure.
- Metabolic Effects: Corticosteroids can cause hyperglycemia and can affect bone mineral density, increasing the risk of osteoporosis. Patients with diabetes or risk factors for osteoporosis should be monitored.
- Eye Conditions: Long-term use of inhaled corticosteroids may cause glaucoma, increased intraocular pressure, or cataracts. Regular eye examinations may be recommended.
- Growth in Children: Inhaled corticosteroids can affect growth velocity in children. Growth should be monitored.
- Paradoxical Bronchospasm: Rare but severe, if it occurs, discontinue the medication immediately and use a rescue inhaler.
- Children Under 5: This combination is generally not approved for use in children younger than 5 years old.
- Key Warnings: Black box warning regarding asthma-related death (when LABA used alone), not for acute symptoms, immunosuppression risk, adrenal suppression, cardiovascular effects.
- Monitoring: Growth in children, eye health, blood sugar, bone mineral density.
- Diuretics: Particularly non-potassium-sparing diuretics (e.g., furosemide, hydrochlorothiazide), can increase the risk of hypokalemia (low potassium levels) when used with formoterol.
- Tricyclic Antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs): These medications can potentiate the cardiovascular effects of formoterol, increasing the risk of arrhythmias and blood pressure changes. Use with extreme caution or avoid if possible.
- QTc-Prolonging Drugs: Both formoterol and, to some extent, corticosteroids can prolong the QTc interval. Concurrent use with other drugs known to prolong the QTc interval (e.g., certain antiarrhythmics, macrolide antibiotics, some antipsychotics) can increase the risk of serious cardiac arrhythmias.
- CYP3A4 Inhibitors: Mometasone is metabolized by the CYP3A4 enzyme in the liver. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat) can increase the systemic exposure to mometasone, potentially leading to increased corticosteroid side effects (e.g., adrenal suppression, Cushing’s syndrome).
Other Corticosteroids: Concurrent use of other systemic corticosteroids (oral or injected) with inhaled mometasone should be carefully monitored due to the potential for additive systemic corticosteroid effects and adrenal suppression.
The dosage of formoterol and mometasone is precisely determined by the healthcare provider based on the patient’s age and asthma severity. It is crucial to follow these instructions exactly.
- Typical Dosage for Asthma (Adults and Children ≥ 12 years):
- Two inhalations (puffs) twice daily (morning and evening).
- Available strengths vary (e.g., 100 mcg mometasone/5 mcg formoterol per puff or 200 mcg mometasone/5 mcg formoterol per puff). The starting dose depends on prior asthma therapy.
- Maximum daily dose: Typically 400 mcg mometasone/20 mcg formoterol per day (e.g., two 200/5 puffs twice daily).
- Typical Dosage for Asthma (Children 5 to < 12 years):
- Two inhalations (puffs) twice daily (morning and evening) of the lower strength (e.g., 50 mcg mometasone/5 mcg formoterol per puff).
- Maximum daily dose: Typically 200 mcg mometasone/20 mcg formoterol per day.
- Missed Dose: If a dose is missed, take the next dose at the usual time. Do not take a double dose to make up for a missed one.
- Duration: This is a long-term control medication. Do not stop using it suddenly without consulting your doctor.
- Standard: Two puffs twice daily.
- Strengths: Vary by age and asthma severity.
- Maximum: Do not exceed prescribed daily limit.
Consistency: Use regularly for best control; do not stop abruptly.
Formoterol and mometasone combination inhalers are prescription-only medications. They are not available over-the-counter.
The necessity for a prescription is due to several critical factors:
- Complex Disease Management: Asthma is a chronic respiratory condition requiring careful diagnosis, assessment of severity, and individualized long-term management by a healthcare professional.
- Risk Profile: The medication contains a LABA, which carries a “Black Box Warning” regarding increased risk of asthma-related death if used inappropriately (e.g., as monotherapy). This necessitates strict medical supervision. The ICS component also has systemic effects and potential side effects that require monitoring.
- Proper Usage and Education: Correct inhalation technique is essential for the medication to be effective. Patients need clear instructions on how to use the inhaler, the difference between a controller and a rescue medication, and when to seek immediate medical attention for worsening symptoms or side effects (like oral thrush).
- Drug Interactions and Monitoring: The potential for significant drug interactions and the need to monitor for side effects (e.g., adrenal suppression, bone density, eye health, growth in children, blood sugar) require ongoing medical oversight.
- Stepped-Care Approach: In asthma management, these combinations are part of a stepped-care approach, meaning they are introduced when less intensive therapies are insufficient. A doctor determines the appropriate step and adjusts therapy as needed.
Therefore, this combination medication must be prescribed and its use supervised by a qualified healthcare professional, such as a pulmonologist, allergist, or general practitioner experienced in managing asthma.
What is this combination used for? Maintenance treatment of asthma in patients ≥5 years old.
2. What drug classes are involved?
3. What is the brand name? Dulera (available as a metered-dose inhaler)
4. What strengths are available?
5. How is it administered? Inhaled orally via MDI, 2 inhalations twice daily.
6. Is it used for COPD? No—not approved for COPD treatment.
7. What are common side effects? Headache, sore throat, sinus pain, hoarseness, oral thrush (candidiasis), and cough.
8. Can it cause serious reactions? Yes—asthma-related death (if LABA used alone), paradoxical bronchospasm, adrenal suppression, and growth suppression in children.
9. Is it safe during pregnancy? Use only if clearly needed; consult a healthcare provider.
10. Is a prescription required? Yes, it is prescription-only.
11. Is it available in Pakistan? Availability may vary; check with pulmonology clinics or pharmacies.
12. Can it be used for acute asthma attacks? No—not a rescue inhaler; use a short-acting beta agonist (e.g., salbutamol) for quick relief.
13. What precautions should be taken? Rinse mouth after use to prevent oral thrush; monitor for adrenal suppression and growth in children.
14. What makes it different from other ICS/LABA combos? Dulera contains formoterol (fast onset) and mometasone (potent ICS), offering both rapid and sustained control.
15. Can it be used in children? Yes—approved for children ≥5 years.
16. How fast does it work? Formoterol acts within 15 minutes; mometasone provides anti-inflammatory effects over time.
17. How long does it last? Each dose provides 12-hour control.
18. What monitoring is needed? Pulmonary function, oral health, adrenal function, and growth in pediatric patients.
19. What are contraindications? Primary treatment of status asthmaticus or acute asthma episodes; hypersensitivity to ingredients.
20. Can it be used with other inhalers? Avoid duplication with other LABAs or ICS; may be combined with rescue inhalers.
